Analysts expect that Iqvia Holdings Inc (NYSE:IQV) will announce sales of $2.14 billion for the current quarter, Zacks reports. Nine analysts have provided estimates for Iqvia’s earnings, with estimates ranging from $2.13 billion to $2.15 billion. Iqvia reported sales of $1.95 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.7%. The company is scheduled to report its next earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Iqvia will report full-year sales of $2.14 billion for the current fiscal year, with estimates ranging from $8.02 billion to $8.06 billion. For the next year, analysts anticipate that the firm will post sales of $8.53 billion per share, with estimates ranging from $8.49 billion to $8.61 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Iqvia.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The business had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same period in the prior year, the firm earned $1.00 EPS. The company’s revenue for the quarter was up 77.6% on a year-over-year basis.

A number of research analysts have weighed in on IQV shares. Mizuho lowered shares of Iqvia from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. BidaskClub lowered shares of Iqvia from a “strong-buy” rating to a “buy” rating in a report on Friday, August 11th. Jefferies Group reaffirmed a “hold” rating and set a $94.00 price target on shares of Iqvia in a report on Friday, August 4th. William Blair upgraded shares of Iqvia from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $70.10 to $93.42 in a research report on Friday, August 4th. Finally, Citigroup boosted their price target on shares of Iqvia from $96.00 to $97.00 and gave the stock a “neutral” rating in a research report on Monday, August 7th. Eleven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $103.15.

In other Iqvia news, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $94.52, for a total transaction of $945,200.00. Following the transaction, the insider now directly owns 27,340 shares in the company, valued at $2,584,176.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Cpp Investment Board Private H sold 6,748,026 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total transaction of $640,185,226.62. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,924,015 shares of company stock worth $752,858,408. Insiders own 6.40% of the company’s stock.

Shares of Iqvia (NYSE IQV) traded up $0.70 during trading on Friday, hitting $102.01. The stock had a trading volume of 2,777,400 shares, compared to its average volume of 1,506,522. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. The firm has a market capitalization of $21,412.94, a P/E ratio of 23.23, a PEG ratio of 1.67 and a beta of 0.65. Iqvia has a 12 month low of $71.90 and a 12 month high of $110.67.

COPYRIGHT VIOLATION WARNING: “$2.14 Billion in Sales Expected for Iqvia Holdings Inc (IQV) This Quarter” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/01/2-14-billion-in-sales-expected-for-iqvia-holdings-inc-iqv-this-quarter-2.html.

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.